{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:03:02Z","timestamp":1768528982769,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":1037,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea"},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"crossref","award":["2013R1A1A2008705"],"award-info":[{"award-number":["2013R1A1A2008705"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["CA178203-01A1"],"award-info":[{"award-number":["CA178203-01A1"]}]},{"name":"University of Chicago Comprehensive Cancer Center","award":["P30 CA014599"],"award-info":[{"award-number":["P30 CA014599"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1093\/annonc\/mdw442","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T01:19:57Z","timestamp":1475198397000},"page":"110-115","source":"Crossref","is-referenced-by-count":45,"title":["Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment"],"prefix":"10.1016","volume":"28","author":[{"given":"E.","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-Y.","family":"Ock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.-Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-W.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.-Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.-L.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Blackler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thyparambil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hembrough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.V.T.","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.-Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-J.","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw442_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdw442_bb0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw442_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12094-011-0637-6","article-title":"Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer","volume":"13","author":"Gravalos","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjc.2014.18","article-title":"Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)","volume":"110","author":"Kurokawa","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw442_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/annonc\/mds528","article-title":"Her2\/neu testing in gastric cancer: evaluating the risk of sampling errors","volume":"24","author":"Warneke","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2014a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2014a randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0045","doi-asserted-by":"crossref","unstructured":"YKangMShawA.OhtsuA randomized, open-label, multicenter, adaptive phase 2\/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma (LA\/MGC\/GEJC). J Clin Oncol 34(suppl 4S); abstr 5. http:\/\/meetinglibrary.asco.org\/content\/159174-173 (3 November 2016, date last accessed).","DOI":"10.1200\/jco.2016.34.4_suppl.5"},{"key":"10.1093\/annonc\/mdw442_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1559-0275-9-5","article-title":"Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue","volume":"9","author":"Hembrough","year":"2012","journal-title":"Clin Proteomics"},{"key":"10.1093\/annonc\/mdw442_bb0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jmoldx.2013.03.002","article-title":"Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue","volume":"15","author":"Hembrough","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1093\/annonc\/mdw442_bb0060","article-title":"Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH","author":"Catenacci","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mdw442_bb0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2015.09.002","article-title":"High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy","volume":"10","author":"Nuciforo","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0070","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.O115.049049","article-title":"Quantification of HER2 by targeted mass spectrometry in formalin-fixed paraffin-embedded breast cancer tissues","author":"Steiner","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"10.1093\/annonc\/mdw442_bb0075","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Gomez-Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw442_bb0080","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/1078-0432.CCR-14-2659","article-title":"Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer","volume":"21","author":"Ock","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw442_bb0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdw442_bb0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdw442_bb0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw442_bb0100","doi-asserted-by":"crossref","unstructured":"PNuciforoSThyparambilP.GalvanQuantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial. Cancer Research 2016; 76(Suppl): abstract P3-07-08. http:\/\/cancerres.aacrjournals.org\/content\/76\/4_Supplement\/P3-07-08 (3 November 2016, date last accessed).","DOI":"10.1158\/1538-7445.SABCS15-P3-07-08"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419319155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419319155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/1\/110\/10296950\/mdw442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:04:27Z","timestamp":1624694667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419319155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0923753419319155"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw442","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}